Home Why UAMS Giving Referring Patients Employment University and Colleges
Breaking Barriers to Cure
About Us
Understanding Multiple Myeloma
Treating Myeloma
Researching the Cure
Becoming a Patient
Patient Resources
Travel/About Little Rock
News Center
How You Can Help
MAKE AN APPOINTMENT MEET OUR STAFF CLINICAL TRIALS CONTACT US
ADD THIS | PRINT | EMAIL THIS PAGE | |
Home » Researching the Cure » Lambert Laboratory of Myeloma Genetics » Publications
Publications
  1. Nakamura, T., Largaespada, D.A., Shaughnessy J, Jenkins, N.A., and Copeland, N.G. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias.  Nat. Genet., 12, 149-153. (1996). PMID:8563752
  2. Nakamura, T., Largaespada, D.A., Lee, M.P., Johnson, L.A., Ohyashiki, K., Toyama, K., Chen, S.J., Willman, C.L., Chen, I.-M., Feinberg, A.P., Jenkins, N.A., Copeland, N.G., and Shaughnessy J. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11) (p15;p15) in human myeloid leukaemia.  Nat. Genet., 12:154-158. (1996). PMID:8563753
  3. Li J, Shen H, Himmel K, Dupuy A, Largaespada D, Nakamura T, Shaughnessy J, Jenkins N, and Copeland N.  Leukaemia disease genes: Large-scale cloning and pathway predictions. Nat. Genet, 23:348-353. (1999). PMID:10610183
  4. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, Epstein J and Barlogie B. High Incidence of Chromosome 13 Deletion In Multiple Myeloma Detected by Multi-Probe Interphase FISH. Blood, 96:1505-1511. (2000). PMID:10942398
  5. Shaughnessy J, Gabrea A, Ying Q, Brents, L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, and Kuehl M Cyclin D3 at 6p21 is dysregulated by recurrent Ig translocations in multiple myeloma.  Blood, 98:217-223. (2001). PMID:11418483
  6. Zhan, F, Hardin, J, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, Van Rhee F, Fassas A, Tricot G, Crowley J, Barlogie B, and Shaughnessy J. Global Gene Expression Profiling Of Multiple Myeloma, Monoclonal Gammopathy Of Undetermined Significance And Normal Bone Marrow Plasma Cells. Blood, 99:1745-1757. (2002). PMID:1181292
  7. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, and Shaughnessy J. Gene Expression Profiling of Normal Human Plasma Cell Differentiation and the Classification Of Multiple Myeloma Based on Similarities to Distinct Stages of Late Stage B-Cell Development. Blood, 101: 1128-1140 (2003).PMID:12393520
  8. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J. A Subset of Multiple Myeloma Harboring the t(4;14)(p16;q32) Translocation Lack FGFR3 Expression but Maintain an IGH/MMSET Fusion Transcript. Blood, 101:2374-6 (2003). PMID:12433679
  9. Tarte K, De Vos J, Zhan F, Klein B, and Shaughnessy J.  Gene Expression Profiling of Plasma Cells and Plasmablasts: Toward a Better Understanding of the Late Stages of B-Cell Differentiation, Blood, 102:592-600 (2003). PMID:12663452
  10. Shaughnessy J Jr. Primer On Medical Genomics. Part IX: Scientific And Clinical Applications Of DNA Microarrays-Multiple Myeloma As A Disease Model. Mayo Clin Proc. 8:1098-109 (2003). PMID:12962165
  11. Tian E, Zhan F, Walker R, Rasmussan E, Ma Y, Barlogie B, Shaughnessy J. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N Eng J Med. 349:2483-2494 (2003). PMID:14695408
  12. Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr.Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol. 2004 Jul;126(1):72-6. PMID: 15198734
  13. Lin P, Mahdavy M, Zhan F, Zhang HZ, Katz RL, Shaughnessy JD. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol. 2004 Oct;17(10):1217-22. PMID: 15195108
  14. Bergsagel P, Kuehl M, Zhan F, Sawyer J, Barlogie B, and Shaughnessy J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 106:296-303. (2005). PMID:15755896
  15. Qiang Y-W, Walsh K, Yao L, Kedei N, Blumberg P, Rubin J, Tosato G,Shaughnessy J, and Rudikoff S. Wnts induce migration/invasion of myeloma plasma. Blood.106:1786-93. (2005). PMID:15886323
  16. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality? Bone Marrow Transplant. 2005 Feb;35(3):215-24. Review. PMID: 15543196
  17. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 354(10):1021-30. (2006). PMID:16525139
  18. Stewart JP, Shaughnessy JD Jr. Role of osteoblast suppression in multiple myeloma. J Cell Biochem. 98(1):1-13 (2006). PMID:16440324
  19. Carrasco R, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Zhan F, Deepak Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson K, Chin L, Shaughnessy Jr. J, Brennan C and DePinho R. High-resolution genomic profiles defines distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 4:313-25 (2006). PMID:16616336
  20. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer J, Hollmig K, Zangari M, Pineda-Roman M, Van Rhee F, Cavallo F, Burington B, John Crowley J, Tricot G, Barlogie B, and Shaughnessy Jr. J.  Frequent Gain of Chromosome Band 1q21 in Plasma Cell Dyscrasias Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and is Related to Prognosis and Disease Progression Following Tandem Stem Cell Transplantation. Blood, 108:1724-32 (2006). PMID:16705089
  21. Zhan F, Huang Y, Colla S, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Hollmig K, Zangari M, Pineda-Roman M, Van Rhee F, Burington B, John Crowley J, Tricot G, Barlogie B, and Shaughnessy Jr. J. The Molecular Classification of Multiple Myeloma, Blood, 108:2020-8 (2006). PMID:16728703
  22. Yaccoby S, Wen Ling W, Zhan F, Walker R Barlogie B, Shaughnessy J. Antibody-Based Inhibition of DKK1 Suppresses Tumor-Induced Bone Resorption and Multiple Myeloma Growth In-Vivo. Blood. 109:2106-11 (2007). PMID:17068150
  23. Dib A, Barlogie B, Shaughnessy JD Jr, Kuehl WM. Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. Blood. 2007 Feb 1;109(3):1337-8. PMID: 17244692
  24. Clines GA, Mohammad KS, Bao Y, Stephens O, Suva L, Shaughnessy J, Fox JW, Chirgwin JM, and Guise TA. Dickkopf Homolog-1 Mediates Endothelin-1-Stimulated New Bone Formation. Mol. Endocrinology 21:486-498 (2007). PMID:17068196
  25. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Hollmig K, Zangari M, Pineda-Roman M, Van Rhee F, Tricot G, Dhodapkar M, and Shaughnessy Jr. J. A Gene Expression Signature Of Benign Monoclonal Gammopathy Evident In Multiple Myeloma Is Linked To Good Prognosis, Blood, 109:1692-1700 (2007). PMID:17023574
  26. Shaughnessy Jr. J, Zhan F, Burington B, Huang Y, Hanamura I, Hollmig K, Zangari M, Pineda-Roman M, Van Rhee F, Tricot G, Crowley J, and Barlogie B. A Validated Gene Expression Signature of High Risk Multiple Myeloma is Defined by Deregulated Expression of Genes Mapping to Chromosome 1. Blood. 109:2276-2284 (2007). PMID:17105813
  27. Colla S, Zhan F, Yaccoby S, Barlogie B, Shaughnessy J. The Oxidative Stress Response Regulates DKK1 Expression Through the JNK Signaling Cascade in Multiple Myeloma Plasma Cells, Blood. 109:4470-4477 (2007). PMID:17255354
  28. Knobloch J, Shaughnessy Jr J, Rüther U. Thalidomide Induces Limb Deformities by Perturbing the Bmp/Wnt/Dkk1 pathway. FASEB J. 21:1410-1421 (2007). PMID:17283219
  29. Zhan F, Colla S, Xu W, Stewart JP, Barlogie B, and Shaughnessy Jr J, CKS1B, over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through SKP2/p27Kip1-Dependent and Independent Mechanisms, Blood. 109:4995-5001 (2007). PMID:17303695
  30. Shaughnessy JD Jr, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M,Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y,  Grazziutti M, Epstein J, Crowley J, Barlogie B.  Testing standard and genetic parameters in 220 patients with multiple Myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 137:530-536 (2007). PMID:17489983
  31. Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD Jr, Epstein J, Kwak LW, Yi Q. DKK1 is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 110:1587-94 (2007). PMID:17515399
  32. Annunziata CM, Davis RE, Bellamy W, Santra M, Gupta S, DR Williams, Demchenko Y, Gabrea A, Lenz G, Wright G, Xiao W, Dave S, Zhao, Hanamura I, Zhan F, Stephens O, Dang L, Barlogie B, Shaughnessy, Jr JD, Kuehl WM and Staudt LM Frequent engagement of the classical NF-kB pathway by diverse genetic abnormalities promotes cell survival in multiple myeloma. Cancer Cell. 12:115-30. (2007). PMID:17692804
  33. Zhan F, Bryant B, Barlogie B, Shaughnessy Jr, JD, Mulligan G, High Risk Myeloma: A Gene Expression-Based Risk Stratification Model for Newly Diagnosed Multiple Myeloma Treated with High Dose Therapy Is Predictive of Outcome in Relapsed Disease Treated with Single Agent Bortezomib and High-Dose Dexamethasone Blood 111:968-9 (2008). PMID:18182586
  34. Qiang, Y.W., Barlogie, B., Rudikoff, S., and Shaughnessy Jr, J.D. 2007. DKK1-Induced Inhibition Of Wnt Signaling In Osteoblast Differentiation Is An Underlying Mechanism Of Bone Loss In Multiple Myeloma. Bone 42:669-680 (2008). PMID:18294945
  35. Qiang YW, Chan Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, andShaughnessy Jr JD. Myeloma-Derived Dickkopf-1 Disrupts Wnt-Regulated Osteoprotegerin and RANKL Production By Osteoblasts: A Potential Mechanism Underlying Osteolytic Bone Lesions In Multiple Myeloma. Blood 112:196-207 (2008). PMID:18305214
  36. Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide.N Engl J Med. 2008 Jul10;359(2):210-2. PMID: 18614793
  37. Gabrea A, Martelli ML, Qi Y, Roschke A, Barlogie B, Shaughnessy JD Jr, Sawyer JR, Kuehl WM.Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.Genes Chromosomes Cancer. 2008 Jul;47(7):573-90.PMID: 18381641
  38. Barlogie B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Crowley J.Making progress in treating multiple myeloma with total therapies: issue of complete remission and more. Leukemia. 2008 Aug;22(8):1650. No abstract available. PMID: 18305551
  39. Tian E, Landowski T, Stephens O, Yaccoby S, Barlogie B, and Shaughnessy Jr. JD. Ellipticine Derivative NSC 338258 Represents a New Generation of Antineoplastic Agents for the Treatment of Multiple Myeloma. Mol Cancer Ther. 7:500-509 (2008). PMID:18319333
  40. Qiang YW, Shaughnessy JD, Jr., and Yaccoby S. Wnt3a Signaling in Bone Inhibits Multiple Myeloma Bone Disease and Tumor Growth. Blood 112:374-382 (2008). PMID:18344425
  41. Burington B, Barlogie B, Zhan F, Crowley J, and Shaughnessy JD, Jr. Tumor Cell Gene Expression Changes Following Short Term in-vivo Exposure to Single Agent Chemotherapeutics Are Related to Survival in Multiple Myeloma. Clin Cancer Res. 14:4821-9 (2008). PMID:18676754
  42. Xiong W, Shaughnessy Jr JD, Starnes S, Johnson S, Huang Y, Barlogie B, Zhan F An Analysis of the Clinical and Biological Significance of TP53 Loss in Multiple Myeloma. Blood 112(10):4235-46 (2008) PMID:18337559
  43. Pinzone JJ, Brett M. Hall BM, Nanda K. Thudi NK, Vonau M, Rosol TJ, Qiang YW and Shaughnessy, Jr. JD The Role of Dickkopf-1 in Bone Development, Homeostasis and Disease. Blood 113(3):517-25 (2009). PMID:18687985
  44. Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Borset M. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood 111(2):806-15 (2008). PMID:17934070
  45. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood. 2009;113:4319–4330. PMID: 19196662
  46. Sawyer JR, Tian E, Thomas E, Koller M, Stangeby C, Sammartino G, Goosen L,Swanson C, Binz RL, Barlogie B, Shaughnessy J. Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 amplicon. Br J Haematol. 2009 Sep 9. [Epub ahead of print]. PMID: 19744130
  47. Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J, Barlogie B. TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3. Br J Haematol.  2009 Aug 21. [Epub ahead of print]. PMID: 19702643
  48. Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B,Shaughnessy JD Jr, Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma.Blood. 2009;114:600–607. PMID: 19458357
  49. Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia.2009 Aug 6. [Epub ahead of print]. PMID: 19657360
  50. Zhou Y, Nair B, Shaughnessy JD Jr, Cartron MA, Haessler J, Anaissie E, van Rhee F, Crowley J, Barlogie B. Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.  Br J Haematol. 2009;145:637–641. PMID: 19344415
Disclaimer| Terms of Use| Privacy| Site Map| Contact Us © Copyright 2010 UAMS Pencil